» Articles » PMID: 22352731

Legalon® SIL: the Antidote of Choice in Patients with Acute Hepatotoxicity from Amatoxin Poisoning

Overview
Date 2012 Feb 23
PMID 22352731
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

More than 90% of all fatal mushroom poisonings worldwide are due to amatoxin containing species that grow abundantly in Europe, South Asia, and the Indian subcontinent. Many cases have also been reported in North America. Initial symptoms of abdominal cramps, vomiting, and a severe cholera-like diarrhea generally do not manifest until at least six to eight hours following ingestion and can be followed by renal and hepatic failure. Outcomes range from complete recovery to fulminant organ failure and death which can sometimes be averted by liver transplant. There are no controlled clinical studies available due to ethical reasons, but uncontrolled trials and case reports describe successful treatment with intravenous silibinin (Legalon® SIL). In nearly 1,500 documented cases, the overall mortality in patients treated with Legalon® SIL is less than 10% in comparison to more than 20% when using penicillin or a combination of silibinin and penicillin. Silibinin, a proven antioxidative and anti-inflammatory acting flavonolignan isolated from milk thistle extracts, has been shown to interact with specific hepatic transport proteins blocking cellular amatoxin re-uptake and thus interrupting enterohepatic circulation of the toxin. The addition of intravenous silibinin to aggressive intravenous fluid management serves to arrest and allow reversal of the manifestation of fulminant hepatic failure, even in severely poisoned patients. These findings together with the available clinical experience justify the use of silibinin as Legalon® SIL in Amanita poisoning cases.

Citing Articles

Mushroom poisoning: An updated review.

Tugcan M, Acikalin Akpinar A Turk J Emerg Med. 2025; 25(1):10-16.

PMID: 39882097 PMC: 11774429. DOI: 10.4103/tjem.tjem_129_24.


Beneficial Effect of Fenofibrate in Combination with Silymarin on Parameters of Hereditary Hypertriglyceridemia-Induced Disorders in an Animal Model of Metabolic Syndrome.

Soukop J, Kazdova L, Huttl M, Malinska H, Markova I, Oliyarnyk O Biomedicines. 2025; 13(1).

PMID: 39857794 PMC: 11763318. DOI: 10.3390/biomedicines13010212.


-Associated Liver Failure: Molecular Mechanisms and Management.

Kayes T, Ho V Int J Mol Sci. 2024; 25(23).

PMID: 39684738 PMC: 11640968. DOI: 10.3390/ijms252313028.


Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders.

Selc M, Macova R, Babelova A Drug Des Devel Ther. 2024; 18:4629-4659.

PMID: 39444787 PMC: 11498047. DOI: 10.2147/DDDT.S483140.


Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.

Jaffar H, Al-Asmari F, Khan F, Rahim M, Zongo E Food Sci Nutr. 2024; 12(5):3097-3111.

PMID: 38726410 PMC: 11077231. DOI: 10.1002/fsn3.4010.


References
1.
ESTES J, Selden L, Gershman L . Mechanism of action of phalloidin on the polymerization of muscle actin. Biochemistry. 1981; 20(4):708-12. DOI: 10.1021/bi00507a006. View

2.
Fiume L, MARINOZZI V, Nardi F . The effects of amanitin poisoning on mouse kidney. Br J Exp Pathol. 1969; 50(3):270-6. PMC: 2072182. View

3.
Enjalbert F, Cassanas G, Rapior S, Renault C, Chaumont J . Amatoxins in wood-rotting Galerina marginata. Mycologia. 2010; 96(4):720-9. DOI: 10.1080/15572536.2005.11832920. View

4.
Blackman J . Clinical approach to toxic mushroom ingestion. J Am Board Fam Pract. 1994; 7(1):31-7. View

5.
Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F . Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009; 50(6):1102-11. DOI: 10.1016/j.jhep.2009.02.023. View